Enzyme Blog

Automating life science regulatory and compliance

Check out our latest blog posts

FDA Tightens Turn-Around Times for Section 522 Studies

FDA Reins in Timelines for Post-Approval Studies

Fate of MCIT Uncertain, But Cures 2.0 a Possible Solution

ML Algorithm for COVID-19 Incurs Large Premarket, Postmarket Studies

FDA Calls for Evaluation of Tests for SARS Variants

FDA, ISO and the Risk Management Quandary

FDA Electromagnetic Compatibility Requirements Growing

IMDRF’s Five-Year Plan Includes Single Review

FDA STeP Program Offers Expedited Review

Remote Audits are Gaining Traction in the Era of COVID-19

FDA Action Plan for AI an Incremental Step

FDA Cybersecurity Communications Likely to be Costly

FDA Posts Microneedling Final Guidance

CDRH Wraps Up Guidance for Nitinol Devices

CDRH Guidance Agenda for FY 2021 Includes CDS Final Guidance

FDA Rolls Out ASCA Pilot Program and Guidance

New FDA Intended Use Rule Provokes New Concerns

FDA Opens Digital Health Center of Excellence

FDA: Work Continues on PreCert Pilot

Breakthrough Devices May Draw Four Years of Medicare Coverage

IMDRF and FDA; Twin Stars in the Med Tech Regulatory Sky

HHS: Rulemaking Required for FDA Regulation of LDTs

FDA and Software Assurance: A Solution to the Validation Impasse

SubtleMR Demonstrates How AI Can Fit into the 510(k) Program

Innovation in SaMD Regulation: Video Games as Medical Devices

FDA, IMDRF Chart Different Courses on Cybersecurity

Combination Products Still a Challenge for FDA

FDA Not Flying Solo in Artificial Intelligence Regulation

Making MDSAP Work for You

The Single Device Audit: Great Hopes Still Unfulfilled

Management System Status for ISO 13485 Complicates FDA Adoption

Suspended Animation; U.S. LDT Regulation Behind EU

Leftovers: Top Five Unfinished FDA Draft Guidances from 2019

ISO 13485 and Part 820: Delays and Opportunities

Best Practices for Handling Customer Complaints Post-Market

Enzyme Offers Support for Teams Dealing with COVID-19

How the Medical Device Sector Can Support Innovation Methods for Developing Digital Health Products

A Guide to Navigating FDA Device Risk Classifications for New Products

What Digital Health companies can expect from the FDA in 2020

Expert Interview: Clinical Trial Planning for Startups with Boulder Clinical Science

2019 RAPS Regulatory Convergence #2019RAPS

Farewell, Dr. Gottlieb, you will be missed

Creating A Culture Of Quality

Our top conference picks for SaMD companies

FDA Pre-Cert v1.0 Explained: 2019 and the Promises of Years to Come

Get more of Enzyme

Popular post tags

Ready to level up? Inquire about certification.

info@enzyme.com or

Ready to do more?

info@enzyme.com or

Enzyme Community

Join the Enzyme Community to dive into educational content, exclusive resources, and more.

Enzyme Certifications

Inquire about leveling up your Enzyme experience with professional instruction.